secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncology Institute, Inc. (TOI)
CIK:        0001799191
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001079973-26-000291
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncology Institute Q4 revenue up 41.6% to $142M, net loss narrows to $7.5M
--------------------------------------------------------------------------

- Q4 2025 revenue $142.0M (+41.6% YoY); gross profit $22.7M (+55.2%).
- Net loss narrowed to $7.5M from $13.2M; adj EBITDA improved to $147K from -$7.8M.
- FY2025 revenue $502.7M (+27.8%); net loss $60.6M vs $64.7M; adj EBITDA -$12.4M vs -$35.7M.
- Added 9 new capitated contracts in CA, FL, NV covering ~260K lives; expanded Elevance, Humana, CarePlus partnerships.
- Cash from operations positive $3.2M in Q4; cash balance $33.6M at year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799191/000107997326000291/0001079973-26-000291-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799191/000107997326000291/toi_8k.htm
  HTML page:      https://secwatch.observer/filing/0001079973-26-000291

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer